StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a report issued on Sunday. The firm issued a sell rating on the stock.
Bio-Path Trading Up 2.6 %
Shares of BPTH opened at $0.82 on Friday. Bio-Path has a one year low of $0.61 and a one year high of $12.37. The stock has a 50 day moving average price of $0.97 and a 200 day moving average price of $1.50.
Institutional Trading of Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors and hedge funds own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- ESG Stocks, What Investors Should Know
- Disney’s Magic Strategy: Reinventing the House of Mouse
- What is the NASDAQ Stock Exchange?
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
